



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/661,588	09/15/2003	Sven Schreder	MERCK-2168D1	8058
23599	7590	06/23/2010		
2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201	MILLEN, WHITE, ZELANO & BRANIGAN, P.C.			
				EXAMINER SPIVACK, PHYLLIS G
				ART UNIT 1614
				PAPER NUMBER ELECTRONIC
		NOTIFICATION DATE 06/23/2010		
		DELIVERY MODE ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

docketing@mwbz.com

Office Action Summary	Application No. 10/661,588	Applicant(s) SCHREDER ET AL.
	Examiner Phyllis G. Spivack	Art Unit 1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 22 March 2010.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1,3-5 and 9-16 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1,3-5 and 9-16 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/GS-68)
Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application
 6) Other: _____

Applicants' Reply filed March 22, 2010 is acknowledged. Claims 1, 3-5 and 9-16 remain under consideration.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 3-5 and 9-16 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 6,646,007. Although the conflicting claims are not identical, they are not patentably distinct from each other because the process set forth in the patent for the production of a pharmaceutical preparation comprising levothyroxine, and optionally liothyronine, yields the identical pharmaceutical formulation that is presently claimed.

Applicant's arguments with respect to claims 1, 3-5 and 9-16 that were rejected in the last Office Action under 35 U.S.C. 103, as being unpatentable over Reynolds et al., U.S. Patent 3,808,332, in view of Jacobs et al., US 2005/0003491, have been considered but are moot in view of the new ground of rejection.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 3-5 and 9-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over Reynolds et al., U.S. Patent 3,808,332, in view of Mitra et al., 5,955,105, and further in view of Remington's Pharmaceutical Sciences.

Reynolds teaches a combination of L-thyroxine and L-triiodothyronine that are physically admixed. Therefore, no organic solvent is present. See column 7, lines 65-67. See Composition I, column 7, where cornstarch is employed as a filler, and Composition J, where lactose and microcrystalline cellulose are employed as fillers. As required by instant claim 3, Reynolds teaches a concentration range of l-thyroxine of 100-300 mcg. Fillers such as lactose, maize starch and microcrystalline cellulose are conventional excipients. A micronized form of levothyroxine with a particle size between 5 and 25 μ m is conventional. Reynolds fails to include gelatin in the combination.

However, Mitra teaches stability problems are associated with pharmaceutical preparations comprising thyroxine. Pharmaceutical preparations containing levothyroxine hormone exhibit a relatively short shelf life, and conditions of high humidity and temperature result in stability issues. See column 1, lines 25-29. Drug-excipient interaction is also a factor determining the stability of a solid dosage formulation comprising levothyroxine. According to Mitra, preferred preparations are prepared in the absence of lactose, glucose, sucrose, polyvinylpyrrolidone and/or Poloxamer. Mitra makes the point that proper selection of a binder, as well as a filler, a disintegrant, a glidant and a lubricant, produces a stable formulation for levothyroxine or other thyroid preparations in solid dosage form.

Remington, which for over 100 years, has been the definitive textbook and reference on the science and practice of pharmacy, teaches materials commonly used

as binders include starch, **gelatin** and sugars, such as sucrose, glucose, dextrose, molasses and lactose. These binders impart a cohesiveness to the table formulation which insures that the tablet remains intact after compression. The quantity of binder used has considerable influence on the characteristics of the compressed tablet. See the top of column two.

Mitra eliminates lactose, glucose, sucrose as suitable binders for pharmaceutical preparations comprising levothyroxine. Therefore, according to Remington, one skilled in the art of formulation chemistry would have reasonably been left with a choice between only starch and gelatin.

The comparative binder utilized in the Declarations filed in February, 2008, hydroxypropylmethylcellulose, is not listed either generally by Remington or, specifically, among those recited by Mitra. Applicants have only provided a comparison of HPMC and gelatin as binders. It cannot therefore be said that gelatin provides an unexpected stabilizing effect without showing comparisons to other known pharmaceutical binders. Applicants have not demonstrated an unexpected result commensurate in scope with the claims.

An improved stability following the utilization of gelatin is not unexpected. Mitra establishes the importance of selecting a suitable binder in order to provide stability to a pharmaceutical preparation comprising a thyroid hormone. Gelatin is conventionally employed as a binder in tablet formulations because of its well-established cohesive qualities. One skilled in the art of formulation chemistry would have been motivated to

prepare pharmaceutical formulations comprising L-thyroxine and, optionally, triiodothyronine, utilizing gelatin as a binder, in a solid form without organic solvents. The teachings of the prior art are suggestive of the present claims.

No claim is allowed. However, favorable consideration would be given to claims drawn to the formulations disclosed in Examples 1-3 on pages 5-7 of the specification.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-0585. The Examiner can normally be reached from 10:30 to 7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Ardin Marschel, can be reached 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Application/Control Number: 10/661,588
Art Unit: 1614

Page 7

June 17, 2010

/Phyllis G. Spivack/
Primary Examiner, Art Unit 1614